Print
31 July 2017
GMP News
“There is a great progress in the creation of Russian vaccines. Over the past 4-5 years, we made a complete transition to Russian-made flu vaccines. They are recognized as the best in the world, and they are currently being purchased in Latin, Central and South America,” said the Minister of Health of the Russian Federation Veronika Skvortsova.
“In the past year, these vaccines allowed to reduce the mortality from flu manyfold. For the first time, we made a transition to the use of Russian inactivated polio vaccines. For the first time, we created our own pentavaccine that can be used against five infections in children, let alone the fact that we have the technology for the most advanced vector vaccines. For example, this includes the vaccine against Ebola. Today, a team of the Ministry of Health is working in Guinea, where it uses this vaccine, because recently there was a repeated outbreak of infection,” said Veronika Skvortsova.
In Russia, the original innovative medicines are being developed in all major medical fields. For example, in St. Petersburg, at the production facilities of Biocad. These are new immunotherapeutic medicines against the wide range of malignant neoplasms and systemic diseases, such as psoriasis, Bekhterev’s disease, and others. These medicines have already shown their efficacy in animal studies, where they exceeded the effectiveness of their foreign analogs, and now they are at the stage of clinical trials. The newly developed medicines include the drugs that reduce the number of metastases in melanoma, some types of lung cancer, kidney cancer, and ureter cancer as early as during the first course of therapy. The Russian science is moving forward.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.